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Risk behaviour and time as covariates for eﬃcacy of the HIV
vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E:
a post-hoc analysis of the Thai phase 3 eﬃcacy trial RV 144
Merlin L Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Prayura Kunasol,
Chirasak Khamboonruang, Prasert Thongcharoen, Patricia Morgan, Michael Benenson, Robert M Paris, Joseph Chiu, Elizabeth Adams,
Donald Francis, Sanjay Gurunathan, Jim Tartaglia, Peter Gilbert, Don Stablein, Nelson L Michael, Jerome H Kim

Summary
Background The Thai phase 3 HIV vaccine trial RV 144 showed modest eﬃcacy of a vaccine against HIV acquisition.
Baseline variables of age, sex, marital status, and risk did not modify vaccine eﬃcacy. We did a post-hoc analysis of the
trial’s data to investigate behavioural risk and eﬃcacy every 6 months after vaccination.
Methods RV 144 was a randomised, multicentre, double-blind, placebo-controlled eﬃcacy trial testing the combination
of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prevent HIV infection or reduce setpoint viral load.
Male and female volunteers aged 18–30 years were recruited from the community. In this post-hoc analysis of the
modiﬁed intention-to-treat population (16 395 participants), HIV risk behaviour was assessed with a self-administered
questionnaire at the time of initial vaccination in the trial and every 6 months thereafter for 3 years. We classiﬁed
participants’ behaviour as low, medium, or high risk. Both the acquisition endpoint and the early viral-load endpoint
were examined for interactions with risk status over time and temporal eﬀects after vaccination. Multiple proportional
hazards regression models with treatment and time-varying risk covariates were analysed.
Findings Risk of acquisition of HIV was low in each risk group, but 9187 (58·2%) participants reported higher-risk
behaviour at least once during the study. Participants classiﬁed as high or increasing risk at least once during followup were compared with those who maintained low-risk or medium-risk behaviour as a time-varying covariate, and the
interaction of risk status and acquisition eﬃcacy was signiﬁcant (p=0·01), with greater beneﬁt in low-risk individuals.
Vaccine eﬃcacy seemed to peak early—cumulative vaccine eﬃcacy was estimated to be 60·5% (95% CI 22–80)
through the 12 months after initial vaccination—and declined quickly. Vaccination did not seem to aﬀect viral load in
either early or late infections.
Interpretation Future HIV vaccine trials should recognise potential interactions between challenge intensity and risk
heterogeneity in both population and treatment eﬀects. The regimen tested in the RV 144 phase 3 trial might beneﬁt
from extended immunisation schedules.
Funding US Army Medical Research and Materiel Command and Division of AIDS, National Institute of Allergy and
Infectious Disease, National Institutes of Health.

Introduction
The results of the phase 3 Thai HIV vaccine trial RV 1441
suggest that a vaccine to prevent acquisition of HIV
infection is possible.1 Although the eﬃcacy was modest
and insuﬃcient to warrant licensure, the study provided
both insights and opportunities for future investigations
into prevention of HIV acquisition. The investigators of
the trial reported two salient, hypothesis-generating
ﬁndings: eﬃcacy seemed greatest in participants at lower
risk for HIV infection compared with the study-deﬁned
high-risk participants, and eﬃcacy seemed maximum
early after administration, but decreased with time.
By contrast with previous eﬃcacy trials for HIV
vaccines, the investigators of RV 144 enrolled mainly
heterosexual people from a population with low
prevalence of HIV.1 Most sexual encounters in RV 144
were unlikely to be associated with risk of HIV
transmission. Few incident cases in the study were from
www.thelancet.com/infection Vol 12 July 2012

well deﬁned high-risk groups such as sex workers,
homosexual and bisexual men, or injecting drug users.
The study was not designed to assess risk-stratiﬁed
eﬃcacy rates and no signiﬁcant interaction between
baseline risk and eﬃcacy was noted,1 although estimated
vaccine eﬃcacy was greater than 40% in the low-risk
groups at baseline, and less than 5% in high-risk
participants. In other diseases, suﬃcient challenge doses
can overwhelm vaccine-induced protective immune
responses.2 The modest success noted in RV 144 could be
because of low viral challenge encountered in the study
population.
Results of non-human-primate challenge studies with
high-dose, intravenous simian immunodeﬁciency virus
(SIV) and pathogenic simian HIV have suggested that
protection from infection is not feasible, but a favourable
modiﬁcation of early viral burden and clinical outcome is
achievable.1 A notable outcome in RV 144 was the absence
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of an eﬀect on viral load in vaccine recipients.1 Most of
these non-human-primate studies used intravenous or
non-physiological, high-dose mucosal challenge doses of
virus. Non-human-primate challenge studies3,4 with repeat,
low-dose mucosal challenge with SIV after vaccination
have shown protection from acquisition with no or variable
eﬀect on viral load or clinical outcome in animals with
breakthrough infection. These ﬁndings are consistent with
the notion that available vaccines against SIV and simian
HIV aﬀord a reduction in acquisition risk in repeat, lowdose mucosal challenge experiments that more closely
model human transmucosal risk. Taken together, these
ﬁndings also suggest that the immune responses
associated with protection from infection are mostly
distinct from those needed for reduction of viraemia and
improved clinical outcome, and are similar to the results of
a summary of data from human trials of breakthrough
infections with the ALVAC-protein boost regimen and an
SIV non-human-primate challenge study.5–7
The RV 144 study was designed to acquire endpoints
over 3·5 years after initial vaccination in more than
16 000 volunteers with 90% statistical power to address
the acquisition objective of 50% eﬃcacy. This population
size and extended follow-up was needed because of
the ten-fold reduction in yearly HIV incidence in Thailand
as a consequence of a vigorous public health campaign
for prevention of HIV/AIDS.8,9 The trial was not designed
to deﬁne time-dependent eﬀects. Nevertheless, the data
suggest that eﬃcacy fell during the extended observation
period, although this ﬁnding was not signiﬁcant.1
We previously reported1 that baseline behavioural risk
characteristics were balanced by treatment group and
associated with diﬀerent placebo group transmission rates
ranging from 0·227 per 100 person-years in the low-risk
group to 0·364 per 100 person-years in the high-risk group
(p=0·005, adjusted for treatment). However, estimates of
vaccine eﬃcacy were not signiﬁcantly diﬀerent when
compared by baseline behavioural risk covariate or any
other parameter assessed, including sex, age, and baseline
partnership status.1
We aimed to further explore, in a post-hoc analysis, the
interaction of risk behaviour and eﬃcacy during the full
course of the study and examine time-dependent
estimates of eﬃcacy to guide the design of future eﬃcacy
trials for HIV vaccines.

Methods
Study design and participants
The main study methods and results including the
screening, enrolment, and retention data by group
have been published previously.1 Brieﬂy, RV 144 was
a randomised, multicentre, double-blind, placebocontrolled eﬃcacy trial testing the combination of the
HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E
to prevent HIV infection or reduce setpoint viral load.
Male and female volunteers aged 18–30 years were
recruited from the community irrespective of HIV risk
532

through a separate screening protocol. Volunteers
received a trial information brieﬁng and gave written
informed consent for participation in the screening
protocol. HIV testing was done, and a follow-up visit at
one of the eight clinical research sites was scheduled for
2–3 weeks later.

Procedures
Volunteers returned for follow-up after the screening
visit, were informed of their HIV test results and, if
seronegative, written informed consent for participation
in the trial was obtained and vaccinations begun. The
protocol was reviewed and approved by the Ethical
Committees of the Ministry of Public Health, the Royal
Thai Army, Mahidol University, and the Human Subjects
Research Review Board of the US Army Medical Research
and Materiel Command.
Vaccinations were given over 24 weeks. The ALVACHIV (vCP1521) or placebo prime was given in the left
arm at weeks 0, 4, 12, and 24. Boosting with AIDSVAX
B/E or placebo was given in the right arm at weeks 12 and
24. The volunteers were followed up with HIV testing
(with appropriate counselling before and after the test)
every 6 months for 3 years. Plasma samples for HIV-1
diagnostics were taken at 0 weeks and 24 weeks, and
every 6 months during the follow-up phase. Research
staﬀ provided education about reduction of risky
behaviours during each vaccination and post-test
counselling visit. The scheme for clinical trial conduct
from screening to treatment and analysis allocation is
published elsewhere.1
Assessment of HIV risk behaviour within the preceding
6 months was done at baseline, 24 weeks, and each
6 month follow-up visit with a self-administered
questionnaire. Volunteers had to classify whether their
everyday behaviour placed them at risk for HIV infection.
The questionnaire then identiﬁed speciﬁc risk behaviours
for HIV acquisition. At each visit, participants were
classiﬁed as high risk if in the past 6 months they met
one of the following criteria: reported that their behaviour
placed them at risk for HIV; had shared needles when
injecting drugs; had two or more sexual partners; had an
HIV-positive sexual partner; had not used a condom
during their last sexual contact (if this sexual contact had
been within the past 6 months) with a sex worker, casual
partner, same-sex partner, drug-injecting partner, or
partner with several partners; had symptoms of a sexually
transmitted infection; had used injecting drugs while in
prison; or were employed at baseline as prostitutes or in
the restaurants and bars where commercial sex
transactions were commonly organised. Volunteers were
deemed low risk if, in the previous 6 months, they
perceived their behaviour did not place them at risk of
HIV infection; had no or one sexual partner and no sex
with sex workers, casual partners, same-sex partners,
HIV-positive partners, drug-injecting partners, or
partners with many partners; or had not been in prison
www.thelancet.com/infection Vol 12 July 2012
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Baseline n (%) Ever n (%)

Low risk
Medium risk
High risk
Placebo

100

Everyday behaviour puts at risk
Needle sharing

Proportion of participants (%)

80

Two to four sex partners

60

20

0
0

26

52

78
104
Week of visit

130

156

182

Figure 1: Proportion of participants in each risk category over time
Participants were classiﬁed as low, medium, or high risk on the basis of
questionnaires administered at baseline and every six months thereafter for
3·5 years.

and reported no symptoms of sexually transmitted
infections. The moderate risk category contained people
with neither low nor high risk—eg, an individual with a
single partner who was a sex worker, injecting drug user,
same-sex partner, or casual partner, but had used
condoms at the last sexual encounter. Individuals who
did not answer an item on the risk questionnaire but
were otherwise inconsistent with the high-risk proﬁle
were classiﬁed as moderate risk. The risk score categories
were devised from baseline responses through use of
combined-group infection results in a blinded fashion.
The terms high, moderate, and low are relative to each
other within this population and do not equate to typical
deﬁnitions in high-risk cohorts.

5613 (36·1%)

133 (0·8%)

1250 (8·2%)

1034 (6·3%)

2745 (17·5%)

More than four sex partners

205 (1·3%)

502 (3·2%)

No condom with casual partner

936 (5·7%)

2490 (15·9%)

No condom with sex-worker partner

40

1620 (9·9%)

62 (0·4%)

291 (1·9%)

No condom with same-sex partner

169 (1·0%)

429 (2·7%)

Condom with HIV-positive partner

227 (1·4%)

597 (3·8%)

No condom with HIV-positive partner

29 (0·2%)

143 (0·9%)

No condom with injecting drug user partner

18 (0·1%)

97 (0·6%)

No condom with many sex partners

258 (1·6%)

753 (4·8%)

Symptoms of sexually transmitted infection

479 (2·9%)

1613 (10·4%)

Injecting drug use while in prison

38 (0·2%)

181 (1·2%)

Occupation as sex worker*

86 (0·5%)

··

470 (2·9%)

··

Works in bar or restaurant where commercial sex transactions happen*
Total number of people in at least one high-risk category

3945 (24·1%)

9187 (58·2%)

*Data collection at baseline only.

Table 1: Behavioural risk indicators for HIV infection at baseline and ever reported during the study

Vaccine

Placebo

Events (n) % infected SE

Events (n) % infected SE

Eﬃcacy†

6 months

5

0·06%

0·028%

11

0·14%

0·042%

54·5%

12 months

12

0·15%

0·044%

30

0·38%

0·069%

59·9%

18 months

24

0·31%

0·063%

43

0·55%

0·083%

44·0%

24 months

32

0·41%

0·072%

50

0·64%

0·090%

35·7%

30 months

37

0·48%

0·078%

58

0·74%

0·097%

36·0%

36 months

45

0·58%

0·086%

65

0·84%

0·103%

30·4%

42 months

51

0·68%

0·096%

74

0·96%

0·111%

29·2%

*Vaccine eﬃcacy=100×(1–% vaccine infection/% placebo infection). †Figures calculated before rounding.

Table 2: Cumulative vaccine eﬃcacy* at 6 month intervals for the modiﬁed intention-to-treat
population determined from Kaplan-Meier infection rates

Statistical analysis
Seven volunteers with prevalent infection at baseline
were excluded, and the modiﬁed intention-to-treat
population was used for the analyses (16 395). To account
for missing data because of people leaving the study
early, we estimated the proportion of individuals with
identiﬁed risk characteristics with the product-limit
survival method. Multiple proportional hazards
regression models with treatment and time-varying risk
covariates were analysed. Eﬃcacy was higher in
participants reporting low or medium risk at baseline
than in those reporting high-risk behaviours at baseline.
Taking all reported behaviours over time into
consideration, participants with risk classiﬁed as high or
ever increasing by the time-varying covariate model were
compared with those who had low or medium risk at
entry and throughout the study. Vaccine eﬃcacy was also
assessed for maximum degree of risk reported during
the study and risk degree reported in the study before
seroconversion. Vaccine eﬃcacy estimates from the
www.thelancet.com/infection Vol 12 July 2012

Kaplan-Meier infection estimates were calculated every
6 months. A non-parametric estimate of the relative
hazard function and conﬁdence intervals were
calculated.10 Descriptive statistics were generated and
pointwise Wilcoxon tests of viral load were done. Twotailed p values are reported.

Role of the funding source
ALVAC-HIV (vCP1521) and ALVAC placebo were supplied by the manufacturer, Sanoﬁ Pasteur. AIDSVAX and
AIDSVAX placebo (VaxGen) were purchased by the
Division of AIDS, National Institute of Allergy and
Infectious Diseases, for the purpose of this trial. The US
Army Medical Research and Materiel Command
participated fully in data collection, determination of the
analysis plan, and interpretation of data. The National
Institute of Allergy and Infectious Diseases also participated in analysis and data interpretation. The
corresponding author had full access to all the data in the
533
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study and had ﬁnal responsibility for the decision to
submit for publication (each of the partners had the
opportunity to comment).

Results
The proportion of participants classiﬁed as low risk
increased, and the numbers in the medium and high risk
100

75

Vaccine eﬃcacy (%)

50

25

0

–25

–50

–75
Pointwise
Simultaneous
–100
0

3

6

9

12

15

21
18
24
Months since entry

27

30

33

36

39

Figure 2: Vaccine eﬃcacy point estimates over time
Vaccine eﬃcacy rates are given over time (red line) with 95% pointwise CIs (green line) and 95% simultaneous CIs
(blue line).

A

B
Vaccine
Placebo

5·00

4·75

Log10 (viral load)

4·50

4·25

4·00

3·75

3·50

0
0

3
Time after infection (weeks)

6

0

3
Time after infection (weeks)

6

Figure 3: Viral load for vaccine and placebo groups
Viral loads measured after infection are plotted for vaccine and placebo groups restricted to those who acquired
HIV within 600 days of ﬁrst vaccination (A) or after 600 days (B). 0 weeks is time of diagnosis of HIV infection.
Error bars show the SE.
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categories fell, during the ﬁrst 52 weeks of the study, and
remained stable thereafter (ﬁgure 1). The distribution of
risk for both overall category and individual risk items
(data not shown) between treatment groups was
balanced. Condom use was stable during the study for all
partner types. The proportions of men and women in
each risk category were similar (data not shown).
Participants could skip a question or report “I don’t know
or I am not sure”, and these response rates fell as the study
progressed. For example, 1218 of 16 373 (7·4%) respondents
declined to answer the question about injecting drug use
with needle sharing at study entry, but at the end of the
study 303 of 14 794 (2·0%) declined to answer, with a small
corresponding increase in reported rates both aﬃrming
and denying this behaviour over time. 105 (34·7%) of the
participants who did not answer at the end of the trial also
did not answer this question at baseline. Although the
rates for individual and overall risk category did not
systematically increase over time, the number of people
who reported a high-risk factor at least once increased
(table 1). Treatment groups did not diﬀer in risk categories
at baseline or with time. At baseline, more people in the
placebo group had seven of the 15 risk characteristics than
in the intervention group, with a maximum excess risk
disparity of 18 participants. More people in the vaccine
group had the other eight risk characteristics. 5613 (36%)
of participants reported a self-assessment of high-risk
behaviour at least once during the study. Generally, all
other speciﬁc risk items were far less common than selfreporting of risk. Taken together, the proportion of
participants self-classiﬁed or assigned to the high-risk
group on the basis of speciﬁc responses rose from 24·1% at
entry to 58·2% when including all timepoints in the study
(table 1). The number of HIV infections was similar in
baseline high-risk (45) and low-risk participants (46)
despite diﬀerent transmission rates because low-risk
participants were more common at baseline. However,
most infections (84) were identiﬁed in participants who
reported high-risk behaviour at baseline or during at least
one subsequent visit. An additional 39 HIV infections
were diagnosed in participants who initially reported lowrisk (n=28, 14 vaccine and 14 placebo) or medium-risk
behaviour (11, ﬁve vaccine and six placebo) and subsequently reported at least one period of higher-risk
behaviour. The interaction of risk with vaccine eﬃcacy was
signiﬁcant (p=0·01) between participants reporting highrisk or increased-risk behaviour at least once and those
reporting medium risk or low risk throughout the study on
a time-varying basis. The vaccine eﬃcacy estimate for
participants who maintained low or medium risk from
entry throughout the entire study was 68% (95% CI 34–84,
p=0·002). We noted little vaccine eﬀect for the high-risk
group (vaccine eﬃcacy 5%, 95% CI –46 to 38).
Although we identiﬁed an interaction with risk, the
most important risk behaviours for HIV transmission
contributed little to the ﬁndings of RV 144. For example,
although injecting drug use with needle sharing was
www.thelancet.com/infection Vol 12 July 2012
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commonly reported (n=1250 [8·2%]), only ﬁve (two vaccine
and three placebo) HIV infections were reported in this
group. In men reporting sex with men, only 16 HIV
infections were noted (eight vaccine and eight placebo).
Vaccine eﬃcacy fell at each interval (table 2), with
endpoint ascertainment after 12 months, but the
interaction of time from ﬁrst immunisation and
outcome was not signiﬁcant (p=0·36).1 Nevertheless,
the early timepoint eﬃcacy estimates reported after
completion of the vaccine series were substantially
greater than those at conclusion of the study—vaccine
eﬃcacy was 54·5% at 6 months and 59·9% at 12 months
compared with 29·2% at 42 months. The transmission
rate for the placebo group varied modestly from
0·38 per 100 person years in year one to 0·26 per
100 person years in the ﬁnal year of the investigation.
In proportional hazards models that speciﬁed the log
hazard ratio (vaccine vs placebo) as various smooth
functions of time (linear, log-linear, quadratic, and
piece-wise cubic polynomials in three or four
segments), results were generally consistent with
eﬃcacy, which was most clearly evident early and
declined from the second year of follow-up to the end of
the study (data not shown). A non-parametric analysis
gave a similar result, with early instantaneous hazards
eﬃcacy falling to 0 by 18 months (ﬁgure 2).
In an additional post-hoc analysis we assessed the
relation between timing of infection and viral load. The
viral-load endpoint was the average of three samples
acquired during the ﬁrst 6 weeks after serodiagnosis of
HIV infection. This endpoint was assessed for acquisition events arising within 600 days of initial vaccination
(a period with high eﬃcacy rate estimates) separately
from events reported after this period when eﬃcacy fell.
We detected no diﬀerence in viral load at any timepoint
after infection or in mean early viral load (the co-primary
endpoint) between the vaccine and placebo groups when
segregated by proximity to vaccination (ﬁgure 3). The
eﬀect of vaccine on viral load did not diﬀer either by
baseline risk group or in participants classiﬁed as high
risk or increased compared with baseline risk.

Discussion
Vaccine eﬃcacy in the RV 144 trial was unrelated to
baseline variables including risk assessment (panel). The
risk assessment variable is signiﬁcant with respect to
outcome when considered over the course of the study.
Further, the eﬃcacy estimate was highest in the ﬁrst
6 months after completion of vaccination and fell rapidly.
Risk of infection is a complex, compound estimate of
several eﬀects but can be simply assessed.11 Aggregate
risk of infection is a function of donor challenge (eg, risk
that source is HIV positive, viral load, presence of
cofactors including sexually transmitted infections and
bleeding), recipient susceptibility (eg, genetically deﬁned
host characteristics, route of infection, presence of
cofactors), and frequency of exposure.
www.thelancet.com/infection Vol 12 July 2012

Panel: Research in context
Systematic review
We systematically searched PubMed with the search terms
“vaccine eﬃcacy”, “HIV vaccine trial”, and “HIV vaccine clinical
study” for HIV vaccine eﬃcacy trials published in English to
identify all randomised controlled trials with behavioural data
and a positive outcome. We did not identify any previous
studies of HIV vaccines showing eﬃcacy. There was no
restriction on dates of publication.
Interpretation
The eﬃcacy and beneﬁt noted in RV 144, which enrolled a
population with a low incidence of HIV infection, fell quickly
after 12 months and accrued mainly to participants who did
not report or perceive themselves to show traditional HIV risk
behaviours. Future studies will need to account for participant
risk and temporal eﬀects. This pox–protein prime boost
regimen might show improved eﬃcacy with extended boosts.

For example, HIV infection in individuals with
deletions of CCR5 are uncommon, but if they are exposed
frequently the cumulative probability of encountering
someone infected with the X4 virus mitigates the
protective beneﬁt of this element of genetic resistance.12
Furthermore, data from human vaccine and challenge
experiments provide convincing evidence that induction
of protective immunity can be overcome with a single
suﬃciently large challenge.2 In non-human primate
studies, to reproducibly and eﬃciently overcome
infectious challenge doses and routes seems to need an
immune response that is unachievable for the current
generation of vaccines. In Vax003, a trial13 that used
AIDSVAX B/E in Thai injecting drug users, the absence
of eﬃcacy might have been because of the stringency of
intravenous challenge when compared with the
intravaginal and intrarectal routes. This stringency could
be because of the circumvention of mucosal barriers and
related genetic bottlenecks or the avoidance of vaccineassociated immune responses at mucosal sites. Several
lines of evidence14–16 suggest that the challenge experienced
by injecting drug users is higher in magnitude and
genetic diversity than both that faced by non-injectingdrug users and that faced by people infected by a nonintravenous route. Possibly, human vaccines tested in
eﬃcacy trials thus far provided only modest time-sensitive
reduction in host susceptibility that was undone by the
aggregate transmission challenge intensity.
Vaccine-induced immune responses can reasonably be
assumed to be independent of volunteer risk status. The
absence of eﬃcacy in high-risk participants in RV 144
could be because of either the higher challenge per
exposure or more frequent exposure, or both, compared
with low-risk participants, with participants infected if the
threshold exposure occurred when immune responses
were inadequate to contain the virus (ﬁgure 4). By contrast,
the population maintaining low risk throughout the study
535
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Figure 4: Interaction of challenge intensity and vaccine eﬃcacy
The black line shows the scale of protective vaccine-induced immunity, which rises after each immunisation and
falls subsequently with time. *High challenge=high dose or frequency. †Low challenge=low dose and frequency.

(in whom eﬃcacy was noted) probably have fewer and
possibly less challenging exposures than the high-risk
group (ﬁgure 4). Frequency and route of exposure, and
cofactors such as sexually transmitted infections are the
basis for consideration of the diﬀerent degrees of
challenge intensity17,18 and, correspondingly, the diﬀerent
magnitudes of vaccine-induced immunity needed to
achieve protection against HIV infection. Furthermore,
we can deduce that vaccine-induced responses must be
both high in magnitude and sustained to achieve similar
eﬃcacy in high-intensity challenge populations. Figure 4
shows a modest, time-limited protective immune
response (as reported in RV 144) and suggests an
additional boost or other augmentation of immune
response would improve eﬃcacy for all risk categories.
A second possibility assumes a more complex model in
which diﬀerent immune responses protect against highrisk and low-risk challenges (eg, responses might occur
in diﬀerent mucosal compartments); the diﬀerential
decay of these protective responses could explain the early
protective eﬀect seen in RV 144. Correlation of immune
responses induced by the ALVAC-HIV and AIDSVAX
B/E regimen to the temporal pattern of protection will be
crucial to guide future vaccine development.
Many researchers think that most HIV vaccines under
development will not prevent acquisition of HIV infection
because they do not stimulate production of neutralising
antibodies.19,20 A more realistic goal for vaccine
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development is thought to be induction of T-cell immunity
to reduce early viral load and slow disease progression, as
has been noted in high-dose challenge studies in nonhuman primates21–23 and inferred from studies of elite
controllers and long-term non-progressors infected with
HIV.24 Despite the apparent absence of neutralising
antibodies against primary HIV isolates or broadly
neutralising activity, the ALVAC prime and AIDSVAX
boost reduced acquisition by 31·2% at 42 months.1 This
regimen did not reduce early viral load even when
examined in the period shortly after vaccination when
anti-acquisition eﬃcacy seems highest. This result is
consistent with the notion that eﬃcacy against acquisition
requires a diﬀerent set of immune eﬀectors from those
needed for reduction in viral load and altered prognosis.
Haynes and colleagues25 reported that IgG against a
conformational glycoprotein 120 V1V2 epitope was
inversely correlated with infection in RV 144. These
data prompted Barouch and co-workers7 to look for
anti-V2 responses in non-human primates vaccinated
with adenovirus type 26 and modiﬁed-vaccinia-ankara
vectored SIV inserts; anti-(SIV)V2 responses were
inversely correlated with infection risk. These ﬁndings
raise additional hypotheses related to the potential decay
of immune responses in the plasma or mucosal
compartments.
The value of a vaccine aﬀording modest protection
in low-challenge-intensity settings as a public health
intervention is questionable, but some researchers argue
that such a vaccine might be cost eﬀective in the Thai
setting.26,27 Nevertheless, the value of protection against
human-to-human transmission of HIV cannot be
underestimated. Further elucidation of the nature of
protection aﬀorded in more permissive settings could
allow optimisation of vaccine strategies to achieve
qualitatively and quantitatively superior vaccines with
expanded eﬃcacy. Our data should be carefully considered
in terms of the inherent risks of a post-hoc analysis and
are intended to identify subjects deserving further
consideration in future eﬃcacy trials. The questions
raised by the data from RV 144 are probably more
important to the future of HIV vaccine development than
are the primary ﬁndings of the trial. Among these issues,
the temporal nature of protection and the interaction with
risk should be studied in more detail in HIV vaccine trials.
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